Skip to main content
Home

oAv Menu

  • Home
  • Patient Care Center
  • Clinical Trials
  • Providers
    • Therapeutics
    • People
    • Places
  • Community Center
    • Community Stories
    • Social Media
    • Community Content
    • Financial Assistance
  • News
    • Community Events
    • Clinical Trials and Research
    • Business
    • News People
    • Happenings
    • Spotlight
    • Fundraising Events
  • Trusted Resources
    • Education
    • Videos & Visuals
  • Event Calendar
  • Login
  • Search
Days Alive & Out of Hospital
ATTRwt Research Study: Days alive and out of hospital in patients with ATTRwt
Aug 19, 2025

News

World Amyloidosis Day
From Rare to Recognised: Shining a Light on Amyloidosis
Oct 16, 2025
OncoDaily
Mohamad Mohty: Are Bispecific Antibodies Game Changers in AL Amyloidosis?
Oct 14, 2025
scientific report
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags
Oct 07, 2025
ARCI
The Double-Drug Dilemma: Should We Combine Treatments in ATTR-CM Amyloidosis?
Oct 02, 2025
intellia therapeutics
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Sep 25, 2025
More in News

Education

ASB
Clinical Utility of AI Based Review of Echocardiography for Diagnosis of Cardiac Amyloidosis
Oct 18, 2025
ScienceDirect
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy
Oct 17, 2025
ASH PUBLICATIONS
Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis
Oct 16, 2025
National Library of Medicine
Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis
Sep 29, 2025
Patient Insights: Think Beyond the Silos
Sep 23, 2025
More in Education

Community Center

A Legacy of Hope: Alison’s Story
A Legacy of Hope: Alison’s Story
Jul 29, 2025
Confirming the Benefit of SGLT2 Inhibitors in People With ATTR Amyloidosis, with Justin Riley Lam, MD
Apr 05, 2025
Health Value Surgery
Dottie’s Travel Alert for TAVR Patients
Apr 02, 2025
ScienceDirect
Advance Insulin Injection Technique and Education With FITTER Forward Expert Recommendations
Apr 01, 2025
BioSpace
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
Mar 31, 2025
More in Community Center

Hot Topics

Healthy Meal Planning
Healthy Meal Planning: Tips for Older Adults
Mar 12, 2025
An Elderly Mother and an Aging Son
An Elderly Mother and an Aging Son: A Journalist’s Caregiving Story
Mar 07, 2025
Patient Safety and Quality: An Evidence-Based Handbook for Nurses
Supporting Family Caregivers in Providing Care
Mar 04, 2025
Caregiver Responsibilities
Live-In Caregivers for Elderly
Feb 26, 2025
Hidden Cost of Caregiving
The Hidden Cost of Caregiving: Stress, Anxiety, and Coping Mechanisms
Jan 23, 2025

Video

Newsletter

Stay informed - subscribe to our newsletter.
The subscriber's email address.

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.

Subscribe

Featured Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Footer menu

  • Home
  • About us
  • Video
  • Galleries
  • Contact
  • Login
  • Privacy Policy
  • Privacy Reminder
  • Terms of use
  • FAQ
  • Code of Conduct

© 2025 Somebody To Talk To, Inc.

Join us on                     
Alnylam Logo external link, opens in a new tabPfizer Logo external link, opens in a new tabBridgebio Logo external link, opens in a new tabAttralus Logo external link, opens in a new tabProthena Logo external link, opens in a new tab
Amyloidosis Foundation Logo external link, opens in a new tab